Other languages Cereno Scientific AB

Equities

CRNO B

SE0008241558

Market Closed - Nasdaq Stockholm Other stock markets 16:29:43 05/06/2024 BST			5-day change	1st Jan Change
4.4 ^SEK	+1.38%		+2.85%	-3.83%

05-23	Cereno Scientific AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-02	Cereno Scientific AB Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cereno Scientific AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23
Cereno Scientific AB Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025	05-02
Cereno Scientific AB Approves Election of New Directors	04-16
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate	04-11
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment	04-10
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014	04-10
Cereno Scientific Receives Patent Expansion in Europe	04-09
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate	03-22
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH	03-21
Cereno Scientific Appoints Don De Bethizy as Board of Directors	03-14
Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH	03-06
Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH	02-29
Cereno Scientific AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21
Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH	02-21
Sweden's Cereno Scientific Appoints Chief Medical Officer	02-13
Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D	02-13
Cereno Scientific AB Appoints Julia Fransson as Director of Business Development	02-02
Cereno Scientific AB Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities	02-01
Cereno Scientific Gets US FDA Approval for Expanded Access to Drug Candidate	01-31
Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension	01-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cereno Scientific AB

Equities

CRNO B

SE0008241558

Other languages

Filters